Currently, CAR-T therapy has demonstrated significant clinical efficacy, and the FDA has approved seven products for the treatment of hematological malignancies: Kymriah, a CD19-specific CAR-T product, was the first to be approved on August 31, 2017, for treating patients with refractory or relapsed B-cell precursor acute lymphoblastic leukemia (B-ALL) (38)
Proc Nat Acad Sci USA 99:511516
What Does the Scientific Evidence Say Efficacy & Safety (2025 Overview) When we examine the medical literature (clinical studies, reviews, regulatory data), a clearer and more cautionary picture emerges: A 2015 review of all published studies up to that time concluded that: there is no robust evidence supporting IV glutathione for skin lightening
The consequent impairment in oxalate homeostasis can trigger localized and systemic inflammation, progressive kidney disease and cardiovascular complications, including sudden cardiac death
Readers should discuss Epitalon with a qualified healthcare professional, especially if they have chronic conditions, take prescription medications, are pregnant or breastfeeding, or have a history of cancer
75 Conversely, forced overexpression of CDO1 in breast cancer cells shifted the flux from glutathione synthesis towards cysteine catabolism, consequently increasing ROS levels and leading to reduced cell viability and growth